MetLife Investment Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-72,468
| Closed | -$2.85M | – | 3027 |
|
|
2023
Q2 | $2.85M | Buy |
72,468
+817
| +1% | +$28.8K | 0.02% | 772 |
|
|
2023
Q1 | $1.74M | Buy |
71,651
+1,618
| +2% | +$35.4K | 0.01% | 967 |
|
|
2022
Q4 | $1.5M | Buy |
70,033
+7,650
| +12% | +$163K | 0.01% | 1018 |
|
|
2022
Q3 | $1.12M | Buy |
62,383
+3,135
| +5% | +$41.1K | 0.01% | 1128 |
|
|
2022
Q2 | $570K | Sell |
59,248
-3,374
| -5% | -$42.4K | ﹤0.01% | 1566 |
|
|
2022
Q1 | $1.05M | Buy |
62,622
+22,329
| +55% | +$330K | 0.01% | 1292 |
|
|
2021
Q4 | $674K | Buy |
40,293
+4,772
| +13% | +$78.2K | 0.01% | 1327 |
|
|
2021
Q3 | $577K | Hold |
35,521
| – | – | 0.01% | 1450 |
|
|
2021
Q2 | $224K | Buy |
35,521
+20,540
| +137% | +$133K | ﹤0.01% | 2089 |
|
|
2021
Q1 | $92.6K | Sell |
14,981
-20,031
| -57% | -$122K | ﹤0.01% | 2254 |
|
|
2020
Q4 | $242K | Sell |
35,012
-1,758
| -5% | -$11.2K | ﹤0.01% | 1872 |
|
|
2020
Q3 | $207K | Buy |
36,770
+14,067
| +62% | +$67.1K | ﹤0.01% | 1847 |
|
|
2020
Q2 | $116K | Buy |
+22,703
| New | +$94.6K | ﹤0.01% | 2188 |
|
MetLife Investment Management's ISEE Position: Q3 2023 in Review
MetLife Investment Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 72,468 shares — an estimated $2.85M sold.
MetLife Investment Management first reported a position in ISEE in Q2 2020 and held it in 13 quarters. The position peaked at $2.85M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- MetLife Investment Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- MetLife Investment Management sold 72,468 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $2.85M.
- MetLife Investment Management first reported a position in IVERIC bio, Inc. Common Stock in Q2 2020 and held it in 13 quarters.
- MetLife Investment Management's IVERIC bio, Inc. Common Stock position peaked at $2.85M in Q2 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.